Travere Therapeutics Turns a Rare Disease Approval into Two Quarters of Accelerating Sales
The Food and Drug Administration granted Travere Therapeutics full approval for FILSPARI in focal segmental glomerulosclerosis on April 13, 2026, the ...
Neutral
0.0